β Blockers in the Secondary Prevention of Gastrointestinal Haemorrhage in Well-Compensated Cirrhotics: A Multicentre Randomised Controlled Study

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To assess the efficacy of β-blockers in the prevention ofrebleeding in selected cirrhotics and to compare the tolerability, safety of and patient compliance with, a selective and a non-selective β-blocker, 94 patients were randomly assigned to propranolol (32), atenolol (32), or placebo (30). Randomisation was made at least 15 days after the bleeding episode. Propranolol was given orally in increasing doses until the resting pulse rate was reduced by approximately 25%. Atenolol was given at a fixed dose of 100 mg/day. Patients were followed up for a mean of 357 days. Rebleeding occurred in 14 patients in the placebo group, 10 in the atenolol group and 8 in the propranolol group. The incidence of rebleeding was significantly lower in patients receiving propranolol than in those on placebo (PR vs PL: p <0.01, log-rank test). Atenolol was less effective than propranolol (AT vs PL: p=0.065, log-rank test) but bleeding-free survival was improved for patients on active drugs compared with those patients on placebo (PR vs PL: p=0.01; AT vs PL: p=0.05, log-rank test). Retrospective analysis revealed that, whatever the type of treatment, abstinence from alcohol was crucial in preventing rebleeding. It was concluded that β-blocker treatment is effective in preventing rebleeding from oesophageal varices in carefully selected alcoholic cirrhotics who survive at least 2 weeks after acute variceal haemorrhage and who cease drinking.

Original languageEnglish
Pages (from-to)35-41
Number of pages7
JournalDrugs
Volume37
Issue number2
DOIs
Publication statusPublished - 1989

Fingerprint

Gastrointestinal Hemorrhage
Secondary Prevention
Propranolol
Atenolol
Placebos
Hemorrhage
Alcohol Abstinence
Esophageal and Gastric Varices
Patient Compliance
Random Allocation
Drinking
Alcohols
Heart Rate
Safety
Survival
Pharmaceutical Preparations
Incidence
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health, Toxicology and Mutagenesis
  • Toxicology

Cite this

@article{a559eaa7ec7c409b8d918e9c3eff4d49,
title = "β Blockers in the Secondary Prevention of Gastrointestinal Haemorrhage in Well-Compensated Cirrhotics: A Multicentre Randomised Controlled Study",
abstract = "To assess the efficacy of β-blockers in the prevention ofrebleeding in selected cirrhotics and to compare the tolerability, safety of and patient compliance with, a selective and a non-selective β-blocker, 94 patients were randomly assigned to propranolol (32), atenolol (32), or placebo (30). Randomisation was made at least 15 days after the bleeding episode. Propranolol was given orally in increasing doses until the resting pulse rate was reduced by approximately 25{\%}. Atenolol was given at a fixed dose of 100 mg/day. Patients were followed up for a mean of 357 days. Rebleeding occurred in 14 patients in the placebo group, 10 in the atenolol group and 8 in the propranolol group. The incidence of rebleeding was significantly lower in patients receiving propranolol than in those on placebo (PR vs PL: p <0.01, log-rank test). Atenolol was less effective than propranolol (AT vs PL: p=0.065, log-rank test) but bleeding-free survival was improved for patients on active drugs compared with those patients on placebo (PR vs PL: p=0.01; AT vs PL: p=0.05, log-rank test). Retrospective analysis revealed that, whatever the type of treatment, abstinence from alcohol was crucial in preventing rebleeding. It was concluded that β-blocker treatment is effective in preventing rebleeding from oesophageal varices in carefully selected alcoholic cirrhotics who survive at least 2 weeks after acute variceal haemorrhage and who cease drinking.",
author = "M. Tommasini and {de Franchis}, R. and A. Sangiovanni and M. Colombo",
year = "1989",
doi = "10.2165/00003495-198900372-00007",
language = "English",
volume = "37",
pages = "35--41",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - β Blockers in the Secondary Prevention of Gastrointestinal Haemorrhage in Well-Compensated Cirrhotics

T2 - A Multicentre Randomised Controlled Study

AU - Tommasini, M.

AU - de Franchis, R.

AU - Sangiovanni, A.

AU - Colombo, M.

PY - 1989

Y1 - 1989

N2 - To assess the efficacy of β-blockers in the prevention ofrebleeding in selected cirrhotics and to compare the tolerability, safety of and patient compliance with, a selective and a non-selective β-blocker, 94 patients were randomly assigned to propranolol (32), atenolol (32), or placebo (30). Randomisation was made at least 15 days after the bleeding episode. Propranolol was given orally in increasing doses until the resting pulse rate was reduced by approximately 25%. Atenolol was given at a fixed dose of 100 mg/day. Patients were followed up for a mean of 357 days. Rebleeding occurred in 14 patients in the placebo group, 10 in the atenolol group and 8 in the propranolol group. The incidence of rebleeding was significantly lower in patients receiving propranolol than in those on placebo (PR vs PL: p <0.01, log-rank test). Atenolol was less effective than propranolol (AT vs PL: p=0.065, log-rank test) but bleeding-free survival was improved for patients on active drugs compared with those patients on placebo (PR vs PL: p=0.01; AT vs PL: p=0.05, log-rank test). Retrospective analysis revealed that, whatever the type of treatment, abstinence from alcohol was crucial in preventing rebleeding. It was concluded that β-blocker treatment is effective in preventing rebleeding from oesophageal varices in carefully selected alcoholic cirrhotics who survive at least 2 weeks after acute variceal haemorrhage and who cease drinking.

AB - To assess the efficacy of β-blockers in the prevention ofrebleeding in selected cirrhotics and to compare the tolerability, safety of and patient compliance with, a selective and a non-selective β-blocker, 94 patients were randomly assigned to propranolol (32), atenolol (32), or placebo (30). Randomisation was made at least 15 days after the bleeding episode. Propranolol was given orally in increasing doses until the resting pulse rate was reduced by approximately 25%. Atenolol was given at a fixed dose of 100 mg/day. Patients were followed up for a mean of 357 days. Rebleeding occurred in 14 patients in the placebo group, 10 in the atenolol group and 8 in the propranolol group. The incidence of rebleeding was significantly lower in patients receiving propranolol than in those on placebo (PR vs PL: p <0.01, log-rank test). Atenolol was less effective than propranolol (AT vs PL: p=0.065, log-rank test) but bleeding-free survival was improved for patients on active drugs compared with those patients on placebo (PR vs PL: p=0.01; AT vs PL: p=0.05, log-rank test). Retrospective analysis revealed that, whatever the type of treatment, abstinence from alcohol was crucial in preventing rebleeding. It was concluded that β-blocker treatment is effective in preventing rebleeding from oesophageal varices in carefully selected alcoholic cirrhotics who survive at least 2 weeks after acute variceal haemorrhage and who cease drinking.

UR - http://www.scopus.com/inward/record.url?scp=0024363594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024363594&partnerID=8YFLogxK

U2 - 10.2165/00003495-198900372-00007

DO - 10.2165/00003495-198900372-00007

M3 - Article

C2 - 2572412

AN - SCOPUS:0024363594

VL - 37

SP - 35

EP - 41

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 2

ER -